

## Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2025

(₹ in lakhs)

Particulars	Quarter Ended			Year Ended
	June-25 (Unaudited)	March-25 (Audited)	June-24 (Unaudited)	March-25 (Audited)
<b>I Revenue</b>				
Revenue from Operations	2917.64	3051.65	3010.47	13469.74
Other Income	66.67	72.04	61.95	234.35
<b>II Total Income</b>	<b>2984.31</b>	<b>3123.68</b>	<b>3072.42</b>	<b>13704.09</b>
<b>III Expenses</b>				
(a) Cost of Materials Consumed	804.94	967.54	777.53	3707.18
(b) Purchase of Stock in trade	224.86	210.27	400.09	1752.37
(c) Change in inventories of Finished Goods, work-in-progress and stock-in-trade	15.97	(58.55)	(28.09)	(137.31)
(d) Employee benefits expense	897.40	951.63	803.50	3409.02
(e) Finance Costs	85.10	52.03	65.07	230.45
(f) Depreciation and amortisation expense	203.36	133.83	167.70	645.31
(g) Other expenses	635.59	639.80	652.05	2949.60
<b>Total Expenses</b>	<b>2867.22</b>	<b>2896.54</b>	<b>2837.85</b>	<b>12556.62</b>
<b>IV Profit / (Loss) before Exceptional Items and Taxes (II - III)</b>	<b>117.09</b>	<b>227.14</b>	<b>234.57</b>	<b>1147.47</b>
<b>V Exceptional Items (Net)</b>	0.00	0.00	0.00	0.00
<b>VI Profit / (Loss) before Tax</b>	<b>117.09</b>	<b>227.14</b>	<b>234.57</b>	<b>1147.47</b>
<b>VII Tax Expenses</b>				
Current Tax	31.00	62.00	40.00	272.41
Deferred Tax	4.67	34.52	19.61	52.34
<b>VIII Net Profit / (Loss) after Tax</b>	<b>81.42</b>	<b>130.62</b>	<b>174.96</b>	<b>822.72</b>
<b>IX Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)</b>	0.00	18.22	0.00	18.22
<b>X Total Comprehensive Income / (Loss)</b>	<b>81.42</b>	<b>148.84</b>	<b>174.97</b>	<b>840.94</b>
Paid up Equity Share Capital (FV ₹ 10/- each)	3569.00	3569.00	3569.00	3569.00
Other Equity				9925.09
<b>XI Basic and diluted earnings per share</b>	0.22	0.36	0.49	2.28

### Notes:

- The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 01st August 2025
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the Unaudited Standalone financials results for the quarter ended 30th June, 2025.

15



For Lyka Labs Limited

*Kunal Gandhi*

Kunal Gandhi  
Managing Director & CEO

DIN: 01516156

Mumbai : 01st August 2025



# D. KOTHARY & CO.

## Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Lyka Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.  
Chartered Accountants  
Firm Registration No. 105335W

Deepak O. Narsaria  
(Partner)

Membership No. 121190  
UDIN: 25121190BMLLXR1483

Place: Mumbai  
Date: 1st August, 2025



**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of Lyka Labs Limited (the "Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of following entities:  
**Subsidiaries**
  - i) Lyka BDR International Limited
  - ii) Lyka Exports Limited
5. The accompanying statement includes the interim financial results and other financial information in respect of 2 subsidiaries, whose interim financial results/information reflects total revenues of Rs. 498.43 lakhs, total net profit/ (loss) after tax of Rs. 18.21 lakhs for the quarter ended June 30, 2025, total comprehensive income of Rs. 18.21 lakhs which have been reviewed by us.





**D. KOTHARY & CO.**  
Chartered Accountants

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For D. Kothary & Co.**  
Chartered Accountants  
Firm Registration No. 105335W

**Deepak O. Narsaria**  
(Partner)  
Membership No. 121190  
UDIN: 25121190BMLLXS7530

Place: Mumbai  
Date: 1st August, 2025



## Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30th June 2025

Particulars		Quarter Ended			Year Ended
		Jun-25	Mar-25	Jun-24	Mar-25
		(unaudited)	(Audited)	(unaudited)	(Audited)
(₹ in lakhs)					
<b>I</b>	<b>Revenue</b>				
	Revenue from Operations	3,302.54	3,342.87	3,011.40	13,849.54
	Other Income	63.09	82.01	55.88	223.17
<b>II</b>	<b>Total Income</b>	<b>3,365.63</b>	<b>3,424.88</b>	<b>3,067.28</b>	<b>14,072.71</b>
<b>III</b>	<b>Expenses</b>				
(a)	Cost of Materials Consumed	804.94	967.54	777.53	3,707.18
(b)	Purchase of Stock in trade	453.00	398.13	400.75	1,987.95
(c)	Change in inventories of finished goods, work-in-progress and stock-in-trade	15.89	(57.20)	(28.09)	(135.96)
(d)	Employee benefits expense	904.84	961.12	818.77	3,463.26
(e)	Finance Costs	85.38	46.81	64.71	227.25
(f)	Depreciation and amortisation expense	211.18	141.66	175.66	676.93
(g)	Other expenses	755.23	665.03	671.70	3,033.61
	<b>Total Expenses</b>	<b>3,230.46</b>	<b>3,123.10</b>	<b>2,881.03</b>	<b>12,960.22</b>
<b>IV</b>	<b>Profit / (Loss) before Exceptional Items and Taxes (II - III)</b>	<b>135.17</b>	<b>301.79</b>	<b>186.25</b>	<b>1,112.49</b>
<b>V</b>	<b>Exceptional Items (Net)</b>	-	-	-	-
<b>VI</b>	<b>Profit / (Loss) before Tax</b>	<b>135.17</b>	<b>301.79</b>	<b>186.25</b>	<b>1,112.49</b>
<b>VII</b>	<b>Tax Expenses</b>				
	Current Tax / Earlier Year Tax	31.00	62.00	40.00	272.65
	Deferred Tax	4.55	36.94	17.30	46.52
<b>VIII</b>	<b>Net Profit / (Loss) after Tax</b>	<b>99.62</b>	<b>202.85</b>	<b>128.95</b>	<b>793.32</b>
<b>IX</b>	<b>Other Comprehensive Income</b>	-	18.09	(0.34)	18.09
<b>X</b>	<b>Total Comprehensive Income / (Loss)</b>	<b>99.62</b>	<b>220.94</b>	<b>128.61</b>	<b>811.41</b>
<b>XI</b>	<b>Profit After Tax Attributed to</b>				
	Owners of the Parent	93.26	177.15	143.91	801.20
	Non-controlling Interest	6.36	25.70	(14.97)	(7.88)
		<b>99.62</b>	<b>202.85</b>	<b>128.94</b>	<b>793.32</b>
<b>XII</b>	<b>Other Comprehensive Income</b>				
	Owners of the Parent	-	18.14	(0.25)	18.14
	Non-controlling Interest	-	(0.05)	(0.09)	(0.05)
		-	<b>18.09</b>	<b>(0.34)</b>	<b>18.09</b>
<b>XIII</b>	<b>Total Comprehensive Income / (Loss)</b>				
	Owners of the Parent	93.26	195.29	143.67	819.34
	Non-controlling Interest	6.36	25.65	(15.05)	(7.93)
		<b>99.62</b>	<b>220.94</b>	<b>128.62</b>	<b>811.41</b>
<b>XIV</b>	<b>Paid up Equity Share Capital (FV Rs.10/- each)</b>	3,569.00	3,569.00	3,569.00	3,569.00
	Other Equity				6,786.02
<b>XV</b>	<b>Basic and diluted earnings per share</b>	0.25	0.49	0.40	2.22

**Notes:**

- 1.The above Unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 1st August 2025
- 2.The Company operates in one business segment i.e. "Pharmaceuticals".
3. The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- 4.During the reporting period, Lyka BDR International Ltd, a subsidiary of the Company, has written off a claim amounting to Rs. 68.48 lakhs due to a product quality, the said goods supplied in the earlier year.
5. The Statutory Auditors have expressed an unqualified opinion on the Unaudited Consolidated financials results for the quarter 30th June 2025



For Lyka Labs Limited



**Kunal Gandhi**  
Managing Director & CEO  
DIN: 01516156

Mumbai: 1st August 2025